Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc (NQ: SGEN )

168.53 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 168.53
Bid (Size) 168.50 (1)
Ask (Size) 175.00 (1)
Prev. Close 168.53
Today's Range 168.53 - 168.53
52wk Range 105.43 - 192.79
Shares Outstanding 181,934,500
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Expert Ratings for Seagen
  Over the past 3 months, 10 analysts have published their opinion on Seagen (NASDAQ:SGEN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
This Analyst Boosts Price Target On Dillard's; Also Check Out Some Other Big PT Changes
JP Morgan raised the price target for Dillard's, Inc. (NYSE: DDS) from $210 to $298. Dillard's shares rose 0.9% to $304.42 in pre-market trading. 
Via Benzinga

Performance

YTD
+6.77%
+6.77%
1 Month
+0.04%
+0.04%
3 Month
+18.23%
+18.23%
6 Month
+35.35%
+35.35%
1 Year
+8.12%
+8.12%

More News

Read More
Seagen Suffers Loss In Arbitration Dispute Over ADC Technology
Via Benzinga
Does Merck Finally Have The Fodder It Needs To Buy Seagen?
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Seagen Q2 Earnings - Better Than Expected, Mum On M&A, Lifts Outlook
Via Benzinga
Seagen Crushes Quarterly Forecasts With Narrower-Than-Expected Losses
Via Investor's Business Daily
Seagen's Bladder Cancer Trial Data Meets Expectation, Analysts Say
Via Benzinga
Seagen Statement on Outcome of Daiichi Sankyo Arbitration
From Seagen Inc.
Via Business Wire
Seattle Genetics's Return On Capital Employed Overview
Via Benzinga
Recap: Seagen Q2 Earnings
Via Benzinga
Seagen Reports Second Quarter 2022 Financial Results
From Seagen Inc.
Via Business Wire
7 Stocks to Buy on the Dip
Via InvestorPlace
Earnings Scheduled For July 28, 2022
Via Benzinga
The 3 Best Market Sectors for the Second Half of 2022
Via InvestorPlace
Analyst Ratings for Seagen
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Seagen Tips Its Hand In Bladder Cancer, But Is It Enough To Woo Merck?
Via Investor's Business Daily
Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate
Via Benzinga
Alibaba, General Electric And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Via Benzinga
Seagen Shares Jump On Positive Data From Urothelial Cancer Trial
Via Benzinga
Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer
From Seagen Inc.
Via Business Wire
$1000 Invested In Seagen 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Why Qudian Shares Jumped Over 40%; Here Are 73 Biggest Movers From Yesterday
Via Benzinga
Why Merck's Rumored $40 Billion Seagen Buyout Is On Shaky Ground
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.